Suppr超能文献

烟碱型乙酰胆碱受体的外源性和内源性非竞争性抑制剂的结合位点。

Binding sites for exogenous and endogenous non-competitive inhibitors of the nicotinic acetylcholine receptor.

作者信息

Arias H R

机构信息

Instituto de Investigaciones Bioquímicas de Bahía Blanca, Consejo Nacional de Investigaciones Científicas y Técnicas, and Universidad Nacional del Sur, Blanca, Argentina.

出版信息

Biochim Biophys Acta. 1998 Aug 21;1376(2):173-220. doi: 10.1016/s0304-4157(98)00004-5.

Abstract

The nicotinic acetylcholine receptor (AChR) is the paradigm of the neurotransmitter-gated ion channel superfamily. The pharmacological behavior of the AChR can be described as three basic processes that progress sequentially. First, the neurotransmitter acetylcholine (ACh) binds the receptor. Next, the intrinsically coupled ion channel opens upon ACh binding with subsequent ion flux activity. Finally, the AChR becomes desensitized, a process where the ion channel becomes closed in the prolonged presence of ACh. The existing equilibrium among these physiologically relevant processes can be perturbed by the pharmacological action of different drugs. In particular, non-competitive inhibitors (NCIs) inhibit the ion flux and enhance the desensitization rate of the AChR. The action of NCIs was studied using several drugs of exogenous origin. These include compounds such as chlorpromazine (CPZ), triphenylmethylphosphonium (TPMP+), the local anesthetics QX-222 and meproadifen, trifluoromethyl-iodophenyldiazirine (TID), phencyclidine (PCP), histrionicotoxin (HTX), quinacrine, and ethidium. In order to understand the mechanism by which NCIs exert their pharmacological properties several laboratories have studied the structural characteristics of their binding sites, including their respective locations on the receptor. One of the main objectives of this review is to discuss all available experimental evidence regarding the specific localization of the binding sites for exogenous NCIs. For example, it is known that the so-called luminal NCIs bind to a series of ring-forming amino acids in the ion channel. Particularly CPZ, TPMP+, QX-222, cembranoids, and PCP bind to the serine, the threonine, and the leucine ring, whereas TID and meproadifen bind to the valine and extracellular rings, respectively. On the other hand, quinacrine and ethidium, termed non-luminal NCIs, bind to sites outside the channel lumen. Specifically, quinacrine binds to a non-annular lipid domain located approximately 7 A from the lipid-water interface and ethidium binds to the vestibule of the AChR in a site located approximately 46 A away from the membrane surface and equidistant from both ACh binding sites. The non-annular lipid domain has been suggested to be located at the intermolecular interfaces of the five AChR subunits and/or at the interstices of the four (M1-M4) transmembrane domains. One of the most important concepts in neurochemistry is that receptor proteins can be modulated by endogenous substances other than their specific agonists. Among membrane-embedded receptors, the AChR is one of the best examples of this behavior. In this regard, the AChR is non-competitively modulated by diverse molecules such as lipids (fatty acids and steroids), the neuropeptide substance P, and the neurotransmitter 5-hydroxytryptamine (5-HT). It is important to take into account that the above mentioned modulation is produced through a direct binding of these endogenous molecules to the AChR. Since this is a physiologically relevant issue, it is useful to elucidate the structural components of the binding site for each endogenous NCI. In this regard, another important aim of this work is to review all available information related to the specific localization of the binding sites for endogenous NCIs. For example, it is known that both neurotransmitters substance P and 5-HT bind to the lumen of the ion channel. Particularly, the locus for substance P is found in the deltaM2 domain, whereas the binding site for 5-HT and related compounds is putatively located on both the serine and the threonine ring. Instead, fatty acid and steroid molecules bind to non-luminal sites. More specifically, fatty acids may bind to the belt surrounding the intramembranous perimeter of the AChR, namely the annular lipid domain, and/or to the high-affinity quinacrine site which is located at a non-annular lipid domain. Additionally, steroids may bind to a site located on the extracellular hydrophi

摘要

烟碱型乙酰胆碱受体(AChR)是神经递质门控离子通道超家族的典范。AChR的药理行为可描述为依次进行的三个基本过程。首先,神经递质乙酰胆碱(ACh)与受体结合。其次,内在偶联的离子通道在ACh结合后打开,随后出现离子通量活动。最后,AChR发生脱敏,即在ACh长期存在的情况下离子通道关闭的过程。这些生理相关过程之间现有的平衡可能会受到不同药物药理作用的干扰。特别是,非竞争性抑制剂(NCI)会抑制离子通量并提高AChR的脱敏速率。使用几种外源性药物研究了NCI的作用。这些药物包括氯丙嗪(CPZ)、三苯基甲基鏻(TPMP+)、局部麻醉药QX - 222和美普罗地芬、三氟甲基碘苯基二氮杂环丙烷(TID)、苯环己哌啶(PCP)、组胺毒素(HTX)、喹吖因和乙锭等化合物。为了了解NCI发挥其药理特性的机制,几个实验室研究了它们结合位点的结构特征,包括它们在受体上各自的位置。本综述的主要目标之一是讨论关于外源性NCI结合位点具体定位的所有现有实验证据。例如,已知所谓的腔内NCI与离子通道中的一系列成环氨基酸结合。特别是CPZ、TPMP+、QX - 222、西松烷类化合物和PCP与丝氨酸、苏氨酸和亮氨酸环结合,而TID和美普罗地芬分别与缬氨酸环和细胞外环结合。另一方面,喹吖因和乙锭被称为非腔内NCI,它们与通道腔外的位点结合。具体而言,喹吖因与距脂质 - 水界面约7埃的非环状脂质结构域结合,乙锭与AChR的前庭结合,其位点距膜表面约46埃,且与两个ACh结合位点等距。非环状脂质结构域被认为位于五个AChR亚基的分子间界面和/或四个(M1 - M4)跨膜结构域的间隙处。神经化学中最重要的概念之一是受体蛋白可以被其特异性激动剂以外的内源性物质调节。在膜嵌入受体中,AChR是这种行为的最佳例子之一。在这方面,AChR受到多种分子如脂质(脂肪酸和类固醇)、神经肽P物质和神经递质5 - 羟色胺(5 - HT)的非竞争性调节。必须考虑到上述调节是通过这些内源性分子与AChR的直接结合产生的。由于这是一个生理相关问题,阐明每个内源性NCI结合位点 的结构成分是有用的。在这方面,这项工作的另一个重要目标是综述与内源性NCI结合位点具体定位相关的所有现有信息。例如,已知神经递质P物质和5 - HT都与离子通道腔结合。特别是,P物质的位点在δM2结构域中发现,而5 - HT及其相关化合物的结合位点推测位于丝氨酸环和苏氨酸环上。相反,脂肪酸和类固醇分子与非腔位点结合。更具体地说,脂肪酸可能与围绕AChR膜内周边的带结合,即环状脂质结构域,和/或与位于非环状脂质结构域的高亲和力喹吖因位点结合。此外,类固醇可能与位于细胞外亲水区域的一个位点结合。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验